| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Departments of Oncology and Immunology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Requests for reprints: Jim Xiang, Research Unit, Division of Health Research, Saskatchewan Cancer Agency, Departments of Oncology and Immunology, College of Medicine, University of Saskatchewan, 20 Campus Drive, Saskatoon, Saskatchewan, Canada S7N 4H4. Phone: 306-655-2917; Fax: 306-655-2910; E-mail: JXiang{at}scf.sk.ca.
Tumor-infiltrating dendritic cells (TID) have an ambivalent role in regulation of tumor regression or growth. However, their precise natures and molecular mechanisms have not been elucidated. In this study, we studied TIDs recruited in progressive P815 and regressive P198 tumors of the same origin. Our data showed that P815 tumors contained CD4+8+ and CD48 TID815 subsets, whereas P198 tumors contained CD4+8+ and CD4+8 TID198 subsets. They similarly stimulate allogeneic T cell proliferation and have nitric oxidemediated cytotoxicity to tumor cells with an exception of CD48 TID815 with less efficiency. The newly identified fourth CD4+8+ TID815 or TID198 subset and the CD4+8 TID198 all express high levels of IFN-
and interleukin (IL)-6, whereas CD48 TID815 secrete a marked level of transforming growth factor-ß. Vaccination of mice with P815 tumor lysatepulsed CD4+8+ TID815 or TID198 and CD4+8 TID198 induced IFN-
secreting Th1 and effective CTL responses leading to protective immunity against P815 tumor, whereas CD48 TID815 stimulated IL-10expressing Tr1 responses leading to immune suppression. Transfer of CD4+ Tr1 cells obtained from CD48 TID815-immunized wild-type, but not IL-10/ mice, into CD4+8+ TID815 immunized mice abolished otherwise inevitable development of antitumor immunity. Taken together, our findings provide an important insight into immunologic alterations in progressive and regressive tumors and an implication for dendritic cellbased approaches in the design of cancer vaccines.
This article has been cited by other articles:
![]() |
S Le Gouvello, S Bastuji-Garin, N Aloulou, H Mansour, M-T Chaumette, F Berrehar, A Seikour, A Charachon, M Karoui, K Leroy, et al. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas Gut, June 1, 2008; 57(6): 772 - 779. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. H. Aberle, S. W. Aberle, R. M. Kofler, and C. W. Mandl Humoral and Cellular Immune Response to RNA Immunization with Flavivirus Replicons Derived from Tick-Borne Encephalitis Virus J. Virol., December 15, 2005; 79(24): 15107 - 15113. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |